Get the Stockscreener App
7.19
4.39%
-0.33
Iteos Therapeutics Inc stock is traded at $7.19, with a volume of 506.90K.
It is down -4.39% in the last 24 hours and down -1.10% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$7.52
Open:
$7.5
24h Volume:
506.90K
Relative Volume:
1.44
Market Cap:
$274.62M
Revenue:
$127.70M
Net Income/Loss:
$-121.25M
P/E Ratio:
-2.2825
EPS:
-3.15
Net Cash Flow:
$-120.32M
1W Performance:
+1.34%
1M Performance:
-1.10%
6M Performance:
-56.95%
1Y Performance:
-36.76%
1-Day Range:
$7.14
$7.65
1-Week Range:
$6.73
$7.65
52-Week Range:
$6.73
$18.75
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
7.19 | 274.62M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet - Yahoo Finance
(ITOS) Investment Report - Stock Traders Daily
Research Analysts Offer Predictions for ITOS Q1 Earnings - Defense World
Analysts Set Expectations for ITOS FY2029 Earnings - Defense World
Wells Fargo & Company Issues Pessimistic Forecast for iTeos Therapeutics (NASDAQ:ITOS) Stock Price - Defense World
HC Wainwright Reaffirms “Buy” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
JPMorgan Chase & Co. Issues Pessimistic Forecast for iTeos Therapeutics (NASDAQ:ITOS) Stock Price - Defense World
iTeos Therapeutics: Poised for Success with Anti-TIGIT Therapies Amidst Competitive Landscape - TipRanks
iTeos Therapeutics (NASDAQ:ITOS) Earns Outperform Rating from Wedbush - Defense World
iTeos fait le point sur ses activités et publie ses résultats financiers pour le quatrième trimestre et l’exercice 2024 - GlobeNewswire Inc.
H.C. Wainwright maintains Buy on ITOS with $21 price target By Investing.com - Investing.com Canada
iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations - Simply Wall St
iTeos Therapeutics: Undervalued with Promising Pipeline and Strong Financial Position - TipRanks
Y Intercept Hong Kong Ltd Purchases Shares of 18,468 iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Iteos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Iteos Therapeutics Inc expected to post a loss of $1.06 a shareEarnings Preview - TradingView
iTeos Therapeutics, Inc. SEC 10-K Report - TradingView
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Can iTeos' $655M War Chest Deliver on Its Promising Cancer Immunotherapy Pipeline? - StockTitan
iTeos Therapeutics (ITOS) to Release Earnings on Wednesday - Defense World
ITOS stock touches 52-week low at $7.09 amid market challenges - MSN
(ITOS) Technical Pivots with Risk Controls - Stock Traders Daily
iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless - Seeking Alpha
Iteos Therapeutics stock hits 52-week low at $7.05 By Investing.com - Investing.com Canada
Iteos Therapeutics stock hits 52-week low at $7.05 - Investing.com India
Financial Contrast: enGene (NASDAQ:ENGN) versus iTeos Therapeutics (NASDAQ:ITOS) - Defense World
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Increases By 5.2% - MarketBeat
Empowered Funds LLC Grows Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Grows By 5.2% - Defense World
(ITOS) Investment Analysis and Advice - Stock Traders Daily
Peapod Lane Capital LLC Invests $836,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Acquired by SG Americas Securities LLC - Defense World
When (ITOS) Moves Investors should Listen - Stock Traders Daily
We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully - Yahoo Finance
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Significant Decline in Short Interest - MarketBeat
(ITOS) Proactive Strategies - Stock Traders Daily
JPMorgan Chase & Co. Purchases 5,368 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Declines By 21.1% - MarketBeat
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy - MSN
iTeos Therapeutics' (ITOS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
(ITOS) On The My Stocks Page - Stock Traders Daily
Barclays PLC Has $1.16 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Invivyd (NASDAQ:IVVD) vs. iTeos Therapeutics (NASDAQ:ITOS) Head-To-Head Comparison - Defense World
Iteos Therapeutics advances anti-TREM2 monoclonal antibody toward IND filing - BioWorld Online
iTeos Therapeutics Plans 2025 Data Presentation on Therapies - TipRanks
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):